Contrast‐enhanced MR imaging of the liver: Comparison between Gd‐BOPTA and mangafodipir

Publisher Website
Google Scholar
Abstract
The purpose of the study was to evaluate the MR contrast agents gadolinium benzyloxypropionictetro‐acetate (Gd‐BOPTA) and Mangafodipir for liver enhancement and the lesion‐liver contrast on T1W spin‐echo (SE) and gradient‐recalled‐echo (GRE) images. Fifty‐one patients (three groups of 17 patients each) with known or suspected liver lesions were evaluated with T1W SE (300/12) and GRE (77‐80/2.3‐2.5/80°) images before and after intravenous (IV) Gd‐BOPTA (0.1 or 0.05 mmol/kg) or Mangafodipir (5 μmol/kg) in phase II to III clinical trials. Quantitative analysis by calculating liver signal‐to‐noise ratio (SNR), lesion‐liver contrast‐to‐noise ratio (CNR), and spleen‐liver CNR was performed. Liver SNR and spleen‐liver CNR were always significantly increased postcontrast. SNR was highest after application of 0.1 mmol/kg Gd‐BOPTA (51.3 ± 3.6, P < .05). CNR was highest after Mangafodipir (−22.6 ± 2.7), but this was not significantly different from others (P = .07). Overall, GRE images were superior to SE images for SNR and CNR. Mangafodipir and Gd‐BOPTA (0.1 mmol/kg) provide equal liver enhancement and lesion conspicuity postcontrast. By all criteria, contrast‐enhanced T1‐weighted GRE were comparable to SE images.